Head-to-head · WeighScore
Apex MD vs LaSara Medical Group
By GLP-1 ScorecardUpdated
Score comparison
Apex MD has the higher recorded score — 71.8/100 to 54.5/100.
Apex MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Apex MD advertises a fixed monthly price with quarterly bloodwork. Ask which refund terms apply to the first payment once the order has been processed.
Before you choose
Before comparing the headline prices, the Apex MD review and the LaSara Medical Group review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Apex MD vs MEDGm and CoreAge Rx vs LaSara Medical Group compare each of them with another graded program, and the list of alternatives to Apex MD ranks the programs closest to Apex MD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Lttl review covers one graded close to these two, at 63.5/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Apex MD | LaSara Medical Group |
|---|---|---|
| WeighScore | 71.8/100 | 54.5/100 |
| Grade | C | C |
| Site position | #95 | #486 |
| Semaglutide | $299/mo advertised for the compounded plan with quarterly bloodwork | $289/mo (compounded) |
| Tirzepatide | $399/mo advertised for the compounded plan with quarterly bloodwork | $399/mo (bundle, compounded) |
| Coverage | Confirm eligibility for your treatment and location | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Publishes separate monthly prices for semaglutide and tirzepatide
- The program page includes quarterly bloodwork in the advertised package
- The terms allow requesting a different pharmacy
What to consider
- The terms require 30 days’ notice before renewal processing
- The first-month membership refund provision and the general no-refund rule after processing need to be reconciled for your order
- The public program page does not identify the pharmacy assigned to your prescription
Strengths
- Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
- National telehealth plus an in-person option in Southern California — uncommon hybrid model
- Free initial consultation
- Active promotional pricing (30% off sitewide at the time of review)
- GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles
What to consider
- Legal entity name and state of incorporation not disclosed
- Compounding pharmacy partner not named
- LegitScript certification status not confirmed
- Per-state availability not listed despite the national-telehealth claim
- Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.